High-flow nasal cannula to prevent low oxygen during sedated endoscopy
Tests high-flow nasal oxygen during sedated endoscopy in adults at high risk of sleep apnea.
Plain-language title generated from the registry record
Registry title: High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
Key facts
- Where
- Hangzhou, Jiaxing, and Quzhou, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults at high risk of sleep apnea who are scheduled for a sedated stomach or bowel camera exam (gastroscopy, colonoscopy or both). It tests whether high-flow nasal oxygen lowers low oxygen levels during the exam.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- High risk of obstructive sleep apnea, with a STOP-Bang score of 5 or more. The exam is expected to last no more than 45 minutes.
Main reasons for not taking part
- Bleeding or clotting problems
- Active nose, mouth or throat infection, or fever above 37.5°C (99.5 °F)
- Lung disease needing oxygen, or oxygen level 92% or lower on room air
- Severe heart, kidney (needing dialysis) or liver failure, or ASA status IV or higher
- Pregnant or breastfeeding
Read by machine on 12 November 2026.
Where in China
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaContact: Diansan Su, DrTaking people
- The First Hospital Of JiaxingJiaxing, ChinaContact: Huadong Ni, DrTaking people
- Quzhou people's HospitalQuzhou, ChinaContact: Huiling Yu, DrTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zhejiang University
- Trial code
- NCT07307560
- Record updated
- 4 May 2026
- Original description
Hypoxia represents the most frequent adverse event during propofol-sedated gastrointestinal endoscopy. The STOP-BANG questionnaire serves as a widely adopted, straightforward tool for screening obstructive sleep apnea (OSA) risk, with a score ≥5 identifying high-risk OSA patients who are particularly susceptible to hypoxia under sedation. Although preliminary research from our team suggests that High-Flow Nasal Cannula (HFNC) may lower the incidence of hypoxemia, evidence remains limited and inconsistent in studies specifically targeting high-risk OSA populations. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxia during sedated gastrointestinal endoscopy in patients identified as high-risk for OSA.Read full original descriptionShow less
High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients: A Multicenter Randomized Trial
Hypoxia represents the most frequent adverse event during propofol-sedated gastrointestinal endoscopy. The STOP-BANG questionnaire serves as a widely adopted, straightforward tool for screening obstructive sleep apnea (OSA) risk, with a score ≥5 identifying high-risk OSA patients who are particularly susceptible to hypoxia under sedation. Although preliminary research from our team suggests that High-Flow Nasal Cannula (HFNC) may lower the incidence of hypoxemia, evidence remains limited and inconsistent in studies specifically targeting high-risk OSA populations. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxia during sedated gastrointestinal endoscopy in patients identified as high-risk for OSA.
Inclusion: Age ≥18 years; STOP-Bang score ≥5; Scheduled for sedated gastrointestinal endoscopy (gastroscopy, colonoscopy, or combined gastroscopy + colonoscopy); The estimated duration of the procedure does not exceed 45 minutes; Patients have signed the informed consent form.
Exclusion: Coagulation disorders or bleeding tendency (e.g., oral/nasal bleeding risk, mucosal injury, space-occupying obstructions); Active upper respiratory tract infection (oral, nasal, or pharyngeal), or fever (core temperature >37.5°C); Chronic obstructive pulmonary disease or other acute/chronic pulmonary diseases requiring long-term or intermittent oxygen therapy, or preoperative SpO₂ ≤ 92% on room air; Severe organ dysfunction, including: Cardiac insufficiency (<4 METs), Severe renal insufficiency (requiring dialysis), Diagnosed severe hepatic insufficiency, Increased intracranial pressure, ASA physical status ≥ IV; Known allergy to sedatives (e.g., propofol) or medical adhesives; Other conditions deemed unsuitable by the investigator; Confirmed pregnancy or current breastfeeding; Multiple traumatic injuries; Current participation in another clinical trial.